Arata Azuma-Arata
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
Journal: Respiratory medicine
Published: March 04, 2021
Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
Journal: Respiratory investigation
Published: September 14, 2020
Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Journal: Respiratory investigation
Published: February 13, 2017
Nrf2 Regulates the Risk of a Diesel Exhaust Inhalation-Induced Immune Response during Bleomycin Lung Injury and Fibrosis in Mice.
Journal: International journal of molecular sciences
Published: January 28, 2017
Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
Journal: Respiratory investigation
Published: April 09, 2015
All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.
Journal: Respiratory investigation
Published: March 26, 2015
A case of acute kidney injury caused by granulomatous tubulointerstitial nephritis associated with sarcoidosis and concomitant presence of anti-glomerular basement membrane antibody.
Journal: Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Published: February 02, 2015
A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan.
Journal: Respiratory investigation
Published: July 11, 2014
Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.
Journal: Expert review of respiratory medicine
Published: June 08, 2010
Showing 1-10 of 10
Last Updated: 09/26/2026